Company: BFRG
Filing Date: 2025-03-14
Form Type: 10-K
Source: 0001493152-25-010367
Chunk: 60

Company: BullFrog AI Holdings, Inc.
Filing Date: 2025-03-14
Form: 10-K
Item: Item 1
Chunk 60
---
 data-driven insights to optimize Eleison’s planned clinical trials
for inhaled lipid-complexed cisplatin (ILC) and dibromodulcitol (DBD). These insights are expected to streamline trial efficiency and
improve decision-making for Eleison’s broader oncology pipeline.

Our
Strategy

We
plan to achieve our business objectives by enabling the successful development of drugs and biologics using a precision medicine approach
via our proprietary artificial intelligence platform bfLEAP. The bfLEAP™ platform utilizes both supervised and unsupervised machine
learning; as such, it is able to reveal meaningful connections in the data without the need for a prior hypothesis. Supervised machine
learning uses labeled input and output data, while an unsupervised learning algorithm does not. In supervised learning, the algorithm
“learns” from the training dataset by iteratively making predictions on the data and adjusting for the correct answer. Unsupervised
learning, also known as unsupervised machine learning, uses machine learning algorithms to analyze and cluster unlabeled datasets. These
algorithms discover hidden patterns or data groupings without the need for human intervention. Algorithms used in the bfLEAP™ platform
are designed to handle highly imbalanced data sets to successfully identify combinations of factors that are associated with outcomes
of interest.

Together
with our strategic partners and collaborators, our primary goal is to improve the odds of success at any stage of pre-clinical and clinical
therapeutics development. Our primary business model is improving the success and efficiency of drug development which is accomplished
either through acquisition of drugs or partnerships and collaborations with companies that are developing drugs. We hope to accomplish
this through strategic acquisitions of current clinical stage and failed drugs for in-house development, or through strategic partnerships
with biopharmaceutical industry companies. We are able to pursue our drug asset enhancement business by leveraging a powerful and proven
AI/ML platform (trade name: bfLEAP™) initially derived from technology developed at JHU-APL. We believe the bfLEAP™ analytics
platform is a potentially disruptive tool for analysis of pre-clinical and clinical data sets, such as the robust pre-clinical and clinical
trial data sets being generated in translational R&D and clinical trial settings. In November 2021, we amended our license agreement
with JHU-APL to include additional advanced AI technology. On July 8, 2022, the Company entered into an exclusive, world-wide, royalty-bearing
license